Autonomix Medical, Inc.

Contributing Author

Recent Articles by Autonomix Medical, Inc.

Dec-23	Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment AMIX GlobeNewswire
Dec-18	Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium AMIX GlobeNewswire
Nov-26	Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth AMIX GlobeNewswire
Nov-18	Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules AMIX GlobeNewswire
Nov-17	Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study AMIX GlobeNewswire
Oct-24	Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Conference AMIX GlobeNewswire
Oct-16	Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit AMIX GlobeNewswire
Oct-09	Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology AMIX GlobeNewswire
Oct-02	Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment AMIX GlobeNewswire
Sep-29	Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System AMIX GlobeNewswire
Sep-09	Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual Congress AMIX GlobeNewswire
Sep-04	Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment AMIX GlobeNewswire
Sep-03	Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study AMIX GlobeNewswire
Sep-02	Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference AMIX GlobeNewswire
Aug-20	Autonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based Technology AMIX GlobeNewswire
Aug-18	Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc. AMIX GlobeNewswire
Aug-15	Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech AMIX GlobeNewswire
Aug-14	Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies AMIX GlobeNewswire
Jul-22	Autonomix Medical, Inc. Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference AMIX GlobeNewswire
Jul-22	Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds AMIX GlobeNewswire
Jul-21	Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications AMIX GlobeNewswire
Jul-07	Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment AMIX GlobeNewswire
Jun-30	Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase ("PoC 2") of Proof-of-Concept Human Clinical Study AMIX GlobeNewswire
Jun-27	Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology AMIX GlobeNewswire
Jun-05	Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain AMIX GlobeNewswire
May-15	Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology AMIX GlobeNewswire
May-14	Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event AMIX GlobeNewswire
May-13	Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market AMIX GlobeNewswire
May-05	Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain AMIX GlobeNewswire
May-01	Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain AMIX GlobeNewswire
Apr-30	Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain AMIX GlobeNewswire

Autonomix Medical, Inc.

Recent Articles by Autonomix Medical, Inc.

Upgrade your FINVIZ experience